Host intestinal epithelium and mucosal immune system (None)

The host intestinal epithelium and mucosal immune system constitute a complex, integrated physiological unit that maintains the body's largest interface with the external environment. The intestinal epithelium acts as a selective physical barrier, regulated by tight junction proteins, while the underlying mucosal immune system, including the gut-associated lymphoid tissue (GALT), manages the delicate balance between tolerance of commensal microbes and defense against pathogens (NCBI StatPearls, 2023). Dysregulation of this system is a primary driver of inflammatory bowel diseases (IBD), such as Crohn's disease and ulcerative colitis, where barrier breakdown leads to aberrant immune activation (Nature Reviews Gastroenterology & Hepatology, 2021). Pharmacological targeting of this system does not usually involve a single molecule but rather a network of pathways, including cytokine signaling and leukocyte migration (Frontiers in Immunology, 2020). Modern therapies like vedolizumab specifically target the homing of immune cells to this system, while others like infliximab neutralize inflammatory mediators within the mucosal environment. Understanding the crosstalk within this system is crucial for developing treatments that restore intestinal homeostasis and promote mucosal healing.

Other names

Intestinal mucosal barrierGut-associated lymphoid tissueGALTIntestinal immune systemIntestinal mucosa

Therapeutic modulation involves the neutralization of pro-inflammatory cytokines (e.g., TNF-alpha, IL-12/23), inhibition of lymphocyte trafficking to the gut mucosa via integrin antagonism, and direct anti-inflammatory effects on the epithelial lining.